Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 3
1977 20
1978 16
1979 37
1980 39
1981 34
1982 40
1983 39
1984 50
1985 53
1986 67
1987 48
1988 32
1989 29
1990 31
1991 31
1992 28
1993 33
1994 46
1995 48
1996 51
1997 60
1998 48
1999 65
2000 65
2001 68
2002 86
2003 72
2004 77
2005 75
2006 73
2007 76
2008 76
2009 60
2010 45
2011 61
2012 69
2013 53
2014 56
2015 52
2016 42
2017 37
2018 37
2019 37
2020 32
2021 36
2022 33
2023 31
2024 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,189 results

Results by year

Filters applied: . Clear all
Page 1
Sulindac selectively induces autophagic apoptosis of GABAergic neurons and alters motor behaviour in zebrafish.
Sun W, Wang M, Zhao J, Zhao S, Zhu W, Wu X, Li F, Liu W, Wang Z, Gao M, Zhang Y, Xu J, Zhang M, Wang Q, Wen Z, Shen J, Zhang W, Huang Z. Sun W, et al. Nat Commun. 2023 Sep 2;14(1):5351. doi: 10.1038/s41467-023-41114-y. Nat Commun. 2023. PMID: 37660128 Free PMC article.
Zebrafish larvae exhibit hyperactive behaviour after sulindac exposure. We also found that akt1 is selectively expressed in GABAergic neurons and that SC97 (an Akt1 activator) and exogenous akt1 mRNA can reverse the apoptosis caused by sulindac. ...Finally, we verif …
Zebrafish larvae exhibit hyperactive behaviour after sulindac exposure. We also found that akt1 is selectively expressed in GABAergic …
Sulindac sulfide as a non-immune suppressive gamma-secretase modulator to target triple-negative breast cancer.
Hossain F, Ucar DA, Monticone G, Ran Y, Majumder S, Larter K, Luu H, Wyczechowska D, Heidari S, Xu K, Shanthalingam S, Matossian M, Xi Y, Burow M, Collins-Burow B, Del Valle L, Hicks C, Zabaleta J, Golde T, Osborne B, Miele L. Hossain F, et al. Front Immunol. 2023 Oct 13;14:1244159. doi: 10.3389/fimmu.2023.1244159. eCollection 2023. Front Immunol. 2023. PMID: 37901240 Free PMC article.
Our overarching goal is to replace GSIs with agents that lack their systemic toxicity and ideally, do not affect tumor immunity. We identified sulindac sulfide (SS), the active metabolite of FDA-approved NSAID sulindac, as a potential candidate to replace GSIs. ...
Our overarching goal is to replace GSIs with agents that lack their systemic toxicity and ideally, do not affect tumor immunity. We identifi …
Sulindac-associated choledocholithiasis.
Eda A, Yanaka I, Tamada K, Wada S, Tomiyama T, Sugano K. Eda A, et al. Am J Gastroenterol. 2001 Jul;96(7):2283-5. doi: 10.1111/j.1572-0241.2001.03995.x. Am J Gastroenterol. 2001. PMID: 11467685 No abstract available.
Clinical pharmacokinetics of sulindac. A dynamic old drug.
Davies NM, Watson MS. Davies NM, et al. Clin Pharmacokinet. 1997 Jun;32(6):437-59. doi: 10.2165/00003088-199732060-00002. Clin Pharmacokinet. 1997. PMID: 9195115 Review.
The absorption of sulindac is rapid when given orally. Sulindac is reversibly metabolised to sulindac sulphide which has anti-inflammatory and analgesic properties and is irreversibly metabolised to sulindac sulphone which has been suggested to possess …
The absorption of sulindac is rapid when given orally. Sulindac is reversibly metabolised to sulindac sulphide which ha …
Sulindac hepatotoxicity.
Fagan EA, Walford N, Hodgson HJ. Fagan EA, et al. Gut. 1983 Dec;24(12):1199. doi: 10.1136/gut.24.12.1199. Gut. 1983. PMID: 6642281 Free PMC article. No abstract available.
Sulindac sulfide--induced stimulation of eryptosis.
Zbidah M, Lupescu A, Yang W, Bosc A, Jilani K, Shaik N, Lang F. Zbidah M, et al. Cell Physiol Biochem. 2012;30(4):1072-82. doi: 10.1159/000341483. Epub 2012 Sep 24. Cell Physiol Biochem. 2012. PMID: 23202471 Free article.
BACKGROUND: Sulindac sulfide, a non-steroidal anti-inflammatory drug (NSAID), stimulates apoptosis of tumor cells and is thus effective against malignancy. ...Sulindac sulfide triggered slight but significant hemolysis. Removal of extracellular Ca(2+) significantly …
BACKGROUND: Sulindac sulfide, a non-steroidal anti-inflammatory drug (NSAID), stimulates apoptosis of tumor cells and is thus effecti …
Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium.
Duggan DE. Duggan DE. Drug Metab Rev. 1981;12(2):325-37. doi: 10.3109/03602538108994035. Drug Metab Rev. 1981. PMID: 7040018 Review.
Sulindac is a prodrug which, following absorption, rapidly attains a metabolic equilibrium with its active pharmacophore, the sulfide metabolite. ...It is thus proposed that sulfide, which is oxidized to sulindac in the course of scavenging oxidizing radicals genera
Sulindac is a prodrug which, following absorption, rapidly attains a metabolic equilibrium with its active pharmacophore, the sulfide
Thrombocytopenia and sulindac.
Karachalios GN, Parigorakis JG. Karachalios GN, et al. Ann Intern Med. 1986 Jan;104(1):128. doi: 10.7326/0003-4819-104-1-128_2. Ann Intern Med. 1986. PMID: 3940492 No abstract available.
Sulindac-induced anaphylaxis.
Burrish GF, Kaatz BL. Burrish GF, et al. Ann Emerg Med. 1981 Mar;10(3):154-5. doi: 10.1016/s0196-0644(81)80383-6. Ann Emerg Med. 1981. PMID: 7469157
This communication describes the first known report of sulindac-induced anaphylaxis. A 17-year-old patient who ingested a single tablet of sulindac developed pruritus, hives, and dyspnea. ...
This communication describes the first known report of sulindac-induced anaphylaxis. A 17-year-old patient who ingested a single tabl …
Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets.
Liggett JL, Zhang X, Eling TE, Baek SJ. Liggett JL, et al. Cancer Lett. 2014 May 1;346(2):217-24. doi: 10.1016/j.canlet.2014.01.021. Epub 2014 Jan 29. Cancer Lett. 2014. PMID: 24486220 Free PMC article. Review.
In this review, we summarize updated literature regarding cellular and molecular targets modulated by NSAIDs. Among those NSAIDs, sulindac sulfide and tolfenamic acid are emphasized in this review because these two drugs have been well investigated for their anti-tumorigen …
In this review, we summarize updated literature regarding cellular and molecular targets modulated by NSAIDs. Among those NSAIDs, sulinda
2,189 results